Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 226

1.

Pharmacokinetics and pharmacodynamics of a novel extended-release ciprofloxacin in healthy volunteers.

Washington CB, Hou SY, Campanella C, Hughes N, Brown S, Berner B.

J Clin Pharmacol. 2005 Nov;45(11):1236-44.

PMID:
16239356
2.

Effect of omeprazole on bioavailability of an oral extended-release formulation of ciprofloxacin.

Washington C, Hou E, Hughes N, Berner B.

Am J Health Syst Pharm. 2006 Apr 1;63(7):653-6.

PMID:
16554289
3.

Urinary excretion and bactericidal activity of intravenous ciprofloxacin compared with oral ciprofloxacin.

Naber KG, Theuretzbacher U, Moneva-Koucheva G, Stass H.

Eur J Clin Microbiol Infect Dis. 1999 Nov;18(11):783-9.

PMID:
10614952
4.

Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers.

Zhao Q, Janssens L, Verhaeghe T, Brashear HR, Truyen L.

Curr Med Res Opin. 2005 Oct;21(10):1547-54. Erratum in: Curr Med Res Opin. 2006 Feb;22(2):441.

PMID:
16238894
5.
6.
7.

Ciprofloxacin prolonged-release tablets do not affect warfarin pharmacokinetics and pharmacodynamics.

Washington C, Hou SY, Hughes NC, Campanella C, Berner B.

J Clin Pharmacol. 2007 Oct;47(10):1320-6. Epub 2007 Aug 27.

PMID:
17724088
8.

Comparative study of pharmacokinetics/ pharmacodynamics of ciprofloxacin between 400 mg intravenously every 8 h and 400 mg intravenously every 12 h in patients with gram negative bacilli bacteremia.

Saengsuwan P, Jaruratanasirikul S, Jullangkoon M, Aeinlang N.

J Med Assoc Thai. 2010 Jul;93(7):784-8. Erratum in: J Med Assoc Thai. 2010 Sep;93(9):1119.

PMID:
20649056
9.

Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose.

Wagenlehner FM, Kinzig-Schippers M, Sörgel F, Weidner W, Naber KG.

Int J Antimicrob Agents. 2006 Dec;28(6):551-9. Epub 2006 Nov 13.

PMID:
17101261
10.
11.

Two open-label, randomized, crossover studies assessing the bioequivalence of ofloxacin administered as immediate-and extended-release formulations in healthy subjects.

Marier JF, Ducharme MP, DiMarco M, Di Spirito M, Morelli G, Tippabhotla SK, Badri N, Rampal A, Monif T.

Clin Ther. 2006 Dec;28(12):2070-80.

PMID:
17296463
13.

Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose.

Wagenlehner FM, Kinzig-Schippers M, Tischmeyer U, Wagenlehner C, Sörgel F, Dalhoff A, Naber KG.

Int J Antimicrob Agents. 2006 Jan;27(1):7-14. Epub 2005 Dec 15.

PMID:
16343856
14.
16.

Pharmacokinetics of ciprofloxacin as a tool to optimise dosage schedules in community patients.

Sánchez Navarro MD, Coloma Milano C, Zarzuelo Castañeda A, Sayalero Marinero ML, Sánchez-Navarro A.

Clin Pharmacokinet. 2002;41(14):1213-20.

PMID:
12405867
17.

Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin.

Meagher AK, Forrest A, Dalhoff A, Stass H, Schentag JJ.

Antimicrob Agents Chemother. 2004 Jun;48(6):2061-8.

18.

Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis.

Talan DA, Klimberg IW, Nicolle LE, Song J, Kowalsky SF, Church DA.

J Urol. 2004 Feb;171(2 Pt 1):734-9.

PMID:
14713799
19.
Items per page

Supplemental Content

Write to the Help Desk